Moreau, P., Hebraud, B., Facon, T., Leleu, X., Hulin, C., Hashim, M., . . . Sonneveld, P. (2021). Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison. Immunotherapy, 13(2), . https://doi.org/10.2217/imt-2020-0266
Chicago-Zitierstil (17. Ausg.)Moreau, Philippe, et al. "Front-line Daratumumab-VTd Versus Standard-of-care in ASCT-eligible Multiple Myeloma: Matching-adjusted Indirect Comparison." Immunotherapy 13, no. 2 (2021). https://doi.org/10.2217/imt-2020-0266.
MLA-Zitierstil (9. Ausg.)Moreau, Philippe, et al. "Front-line Daratumumab-VTd Versus Standard-of-care in ASCT-eligible Multiple Myeloma: Matching-adjusted Indirect Comparison." Immunotherapy, vol. 13, no. 2, 2021, https://doi.org/10.2217/imt-2020-0266.